Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation

被引:0
作者
Arakelyan, Nina [1 ,2 ]
Jais, Jean-Philippe [3 ]
Tomowiack, Cecile [4 ]
Colombat, Philippe [5 ]
Berthou, Christian [6 ]
Desablens, Bernard [7 ]
Moles-Moreau, Marie-Pierre [8 ]
Gastinne, Thomas [9 ]
Quittet, Philippe [10 ]
Casassus, Philippe [11 ]
Le Pourhiet-Le Mevel, Annick [12 ]
Ghandour, Christiane [13 ]
Briere, Josette [14 ]
Colonna, Pierre [1 ]
Andrieu, Jean-Marie [1 ]
机构
[1] Paris Descartes Univ, Lab Mol Oncol & Virol, F-75270 Paris 06, France
[2] Victor Dupouy Hosp, Dept Hematol, Argenteuil, France
[3] Univ Paris 05, Lab Biostat, Paris, France
[4] Univ Hosp Ctr, Hematol Oncol & Cellular Therapy Dept, Poitiers, France
[5] Univ Hosp Ctr, Dept Hematol, Tours, France
[6] Univ Hosp Ctr, Dept Hematol, Brest, France
[7] Univ Hosp Ctr, Dept Hematol, Amiens, France
[8] Univ Hosp Ctr, Dept Hematol, Angers, France
[9] Univ Hosp Ctr, Dept Hematol, Nantes, France
[10] Univ Hosp Ctr, Dept Hematol, Montpellier, France
[11] Avicenne Hosp, Dept Hematol, Bobigny, France
[12] Ctr Rene Gauducheau, Dept Hematol, F-44035 Nantes, France
[13] Sevigne Polyclin, Le Mans, France
[14] St Louis Hosp, Pathol Lab, Paris, France
关键词
Hodgkin lymphoma; intermediate stage; partial remission; combined modality therapy; PROGNOSTIC-FACTORS; RADIATION-THERAPY; RANDOMIZED-TRIAL; EXTENDED-FIELD; DISEASE; TRANSPLANTATION; RADIOTHERAPY; MANAGEMENT; CYCLES; ABVD;
D O I
10.3109/10428194.2012.701737
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The H97-I trial (1997-2004) for Hodgkin lymphoma at intermediate stage (HL-I) included 269 patients who were randomized to receive three or four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). The 197 patients who reached complete remission (CR) (73.2%, p = 0.41 between arms) received radiotherapy (RT); their 10-year progression-free survival (PFS) rate was 87.7 +/- 3.0%, similar to that of the 180 patients of a historical control group (HCG) in CR after three ABVD cycles before RT. The 59 patients who reached post-ABVD partial remission (PR) received one course of intensive chemotherapy (i.v., mg/m(2), vindesine 5, adriamycin 90, BCNU 140, etoposide 600, methylprednisolone 600) before RT. In spite of this additional intensive chemotherapy, their PFS rate (78.4 +/- 6.3%) remained significantly lower (p = 0.03) than that of the 197 patients who reached post-ABVD CR, and was similar to that of the 60 patients of the HCG in PR after three ABVD cycles who did not receive additional chemotherapy before RT.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 15 条
[1]   Early Versus Late Intensification for Patients With High-Risk Hodgkin Lymphoma-3 Cycles of Intensive Chemotherapy Plus Low-Dose Lymph Node Radiation Therapy Versus 4 Cycles of Combined Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Myeloablative Chemotherapy With Autologous Stem Cell Transplantation Five-Year Results of a Randomized Trial on Behalf of the GOELAMS Group [J].
Arakelyan, Nina ;
Berthou, Christian ;
Desablens, Bernard ;
de Guibert, Sophie ;
Delwail, Vincent ;
Moles, Marie-Pierre ;
Quittet, Philippe ;
Jais, Jean-Philippe ;
Colonna, Pierre ;
Andrieu, Jean-Marie .
CANCER, 2008, 113 (12) :3323-3330
[2]   The Present: Optimizing Therapy-Too Much or Too Little? [J].
Bartlett, Nancy L. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :108-114
[3]   The Past: What We Have Learned in the Last Decade [J].
Borchmann, Peter ;
Engert, Andreas .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :101-107
[4]   Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients [J].
Colonna, P ;
Jais, JP ;
Desablens, B ;
Harousseau, JL ;
Briere, J ;
Boasson, M ;
Lemevel, A ;
Casassus, P ;
LePrise, PY ;
Guilhot, F ;
Ghandour, C ;
Lejeune, F ;
Andrieu, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1928-1935
[5]   Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and Dacarbazine-Like chemotherapy regimen followed by extended-field, full-dose radiotherapy [J].
Djeridane, M ;
Oudard, S ;
Escoffre-Barbe, M ;
Lacotte-Thierry, L ;
Desablens, B ;
Briére, J ;
Dib, M ;
Cassasus, P ;
Ghandour, C ;
Lamy, T ;
Lejeune, F ;
Simon, M ;
Traullé, C ;
Vigier, M ;
Maisonneuve, H ;
Briére, J ;
Colonna, P ;
Andrieu, JM .
CANCER, 2002, 95 (10) :2169-2179
[6]   Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review [J].
Herbst, Christine ;
Rehan, Fareed A. ;
Brillant, Corinne ;
Bohlius, Julia ;
Skoetz, Nicole ;
Schulz, Holger ;
Monsef, Ina ;
Specht, Lena ;
Engert, Andreas .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03) :494-500
[7]  
KAPLAN HS, 1980, CANCER-AM CANCER SOC, V45, P2439, DOI 10.1002/1097-0142(19800515)45:10<2439::AID-CNCR2820451003>3.0.CO
[8]  
2-1
[9]  
Klimm Beate, 2005, Curr Hematol Rep, V4, P15
[10]   Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease:: 10-year results of a randomized trial [J].
le Maignan, C ;
Desablens, B ;
Delwail, V ;
Dib, M ;
Berthou, C ;
Vigier, M ;
Ghandour, C ;
Atmani, S ;
Casassus, P ;
Maisonneuve, H ;
Le Mevel, A ;
Traullé, C ;
Bernard, M ;
Brière, J ;
Colonna, P ;
Andrieu, JM .
BLOOD, 2004, 103 (01) :58-66